Mode
Text Size
Log in / Sign up

Contrast-enhanced mammography shows 100% NPV for non-enhancing asymmetries in breast cancer screeningContrast-Enhanced Mammography Helps Identify Risks in Breast Cancer Screening

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that no false-negative cancers were observed among 147 non-enhancing asymmetries on contrast-enhanced mammography.

This meta-analysis evaluates the diagnostic utility of contrast-enhanced mammography (CEM) for patients with mammographic or digital breast tomosynthesis detected asymmetries. The analysis synthesized data from 147 non-enhancing asymmetries (NEAs) to determine the reliability of CEM in identifying malignancy.

The primary finding is a high negative predictive value (NPV) for NEAs, with no false-negative cancers observed among the 147 cases. Random-effects pooling yielded an NPV of 0.98 (95% CI, 0.85-0.997), while exact aggregated binomial analysis showed 100% with a conservative 95% lower bound of 97.5%. Additionally, the authors noted that enhancing asymmetries are strongly associated with malignancy, whereas non-enhancing asymmetries are associated with extremely low malignancy risk.

A primary limitation of this evidence is that only four retrospective single-center studies met the inclusion criteria. Furthermore, accuracy and positive predictive value (PPV) varied across different study settings and prevalence rates. These findings suggest that a lack of enhancement on CEM may support specific surveillance strategies due to the associated low malignancy risk, while the presence of enhancement significantly increases the probability of malignancy.

How this fits prior evidence

This finding addresses a gap in the diagnostic pathway for mammographic asymmetries by providing evidence for the use of contrast-enhanced mammography. While previous coverage has focused on surgical techniques like robot-assisted mastectomy and localization methods such as magnetic seeds, this meta-analysis specifically quantifies the predictive value of CEM for non-enhancing asymmetries.

Doctors are looking at how contrast-enhanced mammography (CEM) helps identify risks in patients with specific types of breast tissue irregularities. This review looked at 147 cases where certain areas did not show enhancement during imaging. The study found that when these areas do not show any enhancement, the risk of cancer is extremely low.

The data showed no false-negative cancers among the 147 non-enhancing cases studied. However, it is important to note that this information comes from a small number of retrospective studies at a single center. Because the evidence is limited to these specific reports, the results may not apply to every patient or clinical setting.

For patients with these types of findings, the main takeaway is that the presence or absence of enhancement helps doctors decide on next steps. If no enhancement is seen, it often supports a strategy of continued monitoring rather than immediate invasive procedures. You should discuss these specific imaging results and your personal risk factors with your doctor.

What this means for you:
Lack of contrast enhancement in certain breast tissue areas is linked to a very low risk of cancer.

Common questions

What does a lack of enhancement mean for my diagnosis?

When an area shows no enhancement on a contrast-enhanced mammogram, it is associated with an extremely low risk of cancer. In the study of 147 cases, no false-negative cancers were found among those that did not enhance. This finding can help your doctor decide if you can safely continue with regular monitoring.

How does this imaging differ from standard mammograms?

Contrast-enhanced mammography (CEM) uses a special agent to highlight blood flow in breast tissue. While standard mammograms look at the structure of the tissue, CEM helps doctors see if an area is active. This specific test helps distinguish between areas that are likely harmless and those that have a higher probability of being malignant.

Is this finding reliable for all patients?

The evidence comes from a small group of only four retrospective studies. Because the data is limited to these specific settings, it may not be applicable to everyone. You should talk to your doctor about how these findings apply to your specific imaging results and your personal health history.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
RATIONALE AND OBJECTIVES: Contrast-enhanced mammography (CEM) is increasingly used to evaluate mammographic or digital breast tomosynthesis (DBT) detected asymmetries. We performed a systematic review and meta-analysis to estimate the diagnostic performance of CEM in this setting, focusing on the negative predictive value (NPV) of non-enhancing asymmetries. MATERIALS AND METHODS: MEDLINE and Embase were searched through October 2025 for studies reporting outcomes of CEM in mammographic/DBT-detected asymmetries with histopathology and/or imaging follow-up. Study selection and data extraction were performed by two readers. Random-effects models with Hartung-Knapp adjustment were used for pooled estimates. Exact aggregated binomial confidence intervals were calculated for zero-event analyses. Risk of bias was assessed using QUADAS-2. RESULTS: Four retrospective single-center studies met inclusion criteria. Across 147 non-enhancing asymmetries (NEAs) with definitive outcomes, no false-negative cancers were observed. Study-level NPVs were 100%. Random-effects pooling yielded an NPV of 0.98 (95% CI, 0.85-0.997; I² = 0%). Exact aggregated binomial analysis demonstrated an NPV of 100% with a conservative 95% lower bound of 97.5%. Enhancing asymmetries, particularly mass-type and suspicious non-mass enhancement, were strongly associated with malignancy. Accuracy and positive predictive value (PPV) varied by study setting and prevalence. CONCLUSION: In appropriately selected mammographic/DBT asymmetries, absence of enhancement on CEM is associated with an extremely low malignancy risk and may support surveillance strategies, whereas enhancement markedly increases malignant probability and refines risk stratification.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.